Table 2 Chemotherapy increases overall survival in high-risk score patients.

All (2004–2009)

 Chemotherapy (yes vs no/unknown)

0.60 (0.47, 0.77)

7.40E−05

0.74 (0.62, 0.87)

2.70E−04

0.90 (0.7, 1.15)

0.40

 Radiation (yes vs no/unknown)

1.22 (0.95, 1.56)

0.12

0.72 (0.62, 0.83)

1.40E−05

0.76 (0.65, 0.88)

2.00E−04

 Age (old vs young)

1.87 (1.37, 2.55)

7.50E−05

2.39 (1.94, 2.93)

9.36E−17

3.42 (2.75, 4.27)

1.05E−27

 Stage (Stage I as baseline)

  Stage II

1.77 (1.35, 2.31)

3.00E−05

1.7 (1.43, 2.02)

3.00E−09

1.53 (1.29, 1.82)

1.10E−06

  Stage III

3.42 (1.62, 7.25)

1.30E−03

4.59 (2.67, 7.88)

3.40E−08

2.91 (1.39, 6.08)

4.54E−03

  Stage IV

6.68 (2.70, 16.53)

4.00E−05

9.43 (4.86, 18.31)

3.30E−11

21.58 (8.84, 52.64)

1.50E−11

 Grade (Grade I as baseline)

  Grade II

1.26 (0.67, 2.34)

0.47

1.29 (1.05, 1.58)

0.01

1.34 (1.14, 1.58)

4.10E−04

  Grade III

1.38 (0.75, 2.54)

0.30

1.85 (1.47, 2.32)

1.40E−07

1.28 (0.98, 1.66)

0.07

 Lymph node (+ vs −)

1.8 (1.23, 2.64)

2.30E−03

1.07 (0.82, 1.39)

0.64

1.08 (0.83, 1.4)

0.56

ER+HER2− (2010–2015)

 Chemotherapy (yes vs no/unknown)

0.62 (0.47, 0.82)

7.70E−04

0.79 (0.66, 0.95)

0.01

0.73 (0.52, 1.01)

0.06

 Radiation (yes vs no/unknown)

0.84 (0.64, 1.09)

0.19

0.7 (0.59, 0.83)

3.30E−05

0.77 (0.66, 0.89)

4.20E−04

 Age (old vs young)

1.37 (0.98, 1.93)

0.07

2.69 (2.07, 3.5)

1.70E−13

3.71 (2.85, 4.82)

1.17E−22

 Stage (Stage I as baseline)

  Stage II

1.56 (1.15, 2.11)

3.97E−03

1.44 (1.17, 1.77)

6.60E−04

1.48 (1.24, 1.77)

2.10E−05

  Stage III

5.60 (3.05, 10.29)

2.60E−08

2.44 (1.45, 4.11)

7.70E−04

2.86 (1.77, 4.61)

1.70E−05

  Stage IV

11.59 (5.82, 23.07)

3.10E−12

19.49 (10.76, 35.28)

1.03E−27

14.44 (7.36, 28.33)

8.10E−15

 Grade (Grade I as baseline)

  Grade II

1.83 (0.74, 4.53)

0.19

1.13 (0.9, 1.42)

0.29

1.1 (0.94, 1.3)

0.24

  Grade III

1.99 (0.81, 4.85)

0.13

1.86 (1.45, 2.39)

1.10E−06

1.31 (1.01, 1.69)

0.05

 Lymph node (+ vs −)

1.37 (0.97, 1.93)

0.08

1.41 (1.11, 1.79)

4.88E−03

1.06 (0.85, 1.32)

0.59

ER+HER2+ (2010–2015)

 Chemotherapy (yes vs no/unknown)

0.48 (0.19, 1.25)

0.13

0.5 (0.15, 1.66)

0.26

0.61 (0.13, 2.81)

0.53

 Radiation (yes vs no/unknown)

0.68 (0.26, 1.76)

0.42

0.33 (0.1, 1.08)

0.07

0.61 (0.21, 1.77)

0.37

 Age (old vs young)

3.75 (0.5, 28.38)

0.20

NA

NA

NA

NA

 Stage (Stage I as baseline)

  Stage II

1.28 (0.45, 3.59)

0.64

0.33 (0.04, 2.64)

0.30

0.69 (0.15, 3.19)

0.63

  Stage III

2.55 (0.23, 28.81)

0.45

0 (0, Inf)

1.00

0 (0, Inf)

1.00

  Stage IV

7.08 (0.68, 73.70)

0.10

NA

NA

0 (0, Inf)

1.00

 Grade (Grade I as baseline)

  Grade II

NA

NA

3.32 (0.41, 26.98)

0.26

1.04 (0.32, 3.42)

0.95

  Grade III

NA

NA

3.62 (0.4, 33.04)

0.25

0.75 (0.08, 6.82)

0.80

 Lymph node (+ vs −)

1.03 (0.26, 4.13)

0.96

4.26 (0.38, 47.95)

0.24

1.33 (0.18, 9.81)

0.78